PortalPublikationenCarfilzomib and dexamethasone vs bortezomib and dexamethason...

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Standard

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. / Ludwig, Heinz; Dimopoulos, Meletios A; Moreau, Philippe; Chng, Wee-Joo; Goldschmidt, Hartmut; Hájek, Roman; Facon, Thierry; Pour, Ludek; Niesvizky, Ruben; Oriol, Albert; Rosiñol, Laura; Suvorov, Aleksandr; Gaidano, Gianluca; Pika, Tomas; Weisel, Katja; Goranova-Marinova, Vesselina; Palumbo, Antonio; Gillenwater, Heidi H; Mohamed, Nehal; Aggarwal, Sanjay; Feng, Shibao; Joshua, Douglas.

in: LEUKEMIA LYMPHOMA, Jahrgang 58, Nr. 10, 10.2017, S. 2501-2504.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ludwig, H, Dimopoulos, MA, Moreau, P, Chng, W-J, Goldschmidt, H, Hájek, R, Facon, T, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Palumbo, A, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S & Joshua, D 2017, 'Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup', LEUKEMIA LYMPHOMA, Jg. 58, Nr. 10, S. 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

APA

Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W-J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., ... Joshua, D. (2017). Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA LYMPHOMA, 58(10), 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

Vancouver

Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hájek R et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA LYMPHOMA. 2017 Okt;58(10):2501-2504. https://doi.org/10.1080/10428194.2017.1298755

Bibtex

@article{20ec670b4624498c82a58803c7f1f981,
title = "Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Dexamethasone, Female, Follow-Up Studies, Humans, Male, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Prognosis, Survival Rate, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "Heinz Ludwig and Dimopoulos, {Meletios A} and Philippe Moreau and Wee-Joo Chng and Hartmut Goldschmidt and Roman H{\'a}jek and Thierry Facon and Ludek Pour and Ruben Niesvizky and Albert Oriol and Laura Rosi{\~n}ol and Aleksandr Suvorov and Gianluca Gaidano and Tomas Pika and Katja Weisel and Vesselina Goranova-Marinova and Antonio Palumbo and Gillenwater, {Heidi H} and Nehal Mohamed and Sanjay Aggarwal and Shibao Feng and Douglas Joshua",
year = "2017",
month = oct,
doi = "10.1080/10428194.2017.1298755",
language = "English",
volume = "58",
pages = "2501--2504",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "10",

}

RIS

TY - JOUR

T1 - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

AU - Ludwig, Heinz

AU - Dimopoulos, Meletios A

AU - Moreau, Philippe

AU - Chng, Wee-Joo

AU - Goldschmidt, Hartmut

AU - Hájek, Roman

AU - Facon, Thierry

AU - Pour, Ludek

AU - Niesvizky, Ruben

AU - Oriol, Albert

AU - Rosiñol, Laura

AU - Suvorov, Aleksandr

AU - Gaidano, Gianluca

AU - Pika, Tomas

AU - Weisel, Katja

AU - Goranova-Marinova, Vesselina

AU - Palumbo, Antonio

AU - Gillenwater, Heidi H

AU - Mohamed, Nehal

AU - Aggarwal, Sanjay

AU - Feng, Shibao

AU - Joshua, Douglas

PY - 2017/10

Y1 - 2017/10

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bortezomib

KW - Dexamethasone

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Multiple Myeloma

KW - Neoplasm Recurrence, Local

KW - Oligopeptides

KW - Prognosis

KW - Survival Rate

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1080/10428194.2017.1298755

DO - 10.1080/10428194.2017.1298755

M3 - SCORING: Journal article

C2 - 28306371

VL - 58

SP - 2501

EP - 2504

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 10

ER -